| Unit Size | Cost | Quantity | Stock |
|---|
Mitoxantrone is an anthracenedione that exhibits immunosuppressive and anticancer chemotherapeutic activities. Mitoxantrone is clinically used to treat multiple sclerosis (MS), breast cancer, non-Hodgkin’s lymphoma, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Mitoxantrone acts as an intercalator, cross-linking and forming complexes in DNA, inhibiting DNA synthesis; it also inhibits Pim-1 kinase.
| Cas No. | 70476-82-3 |
|---|---|
| Purity | ≥98% |
| Formula | C22H28N4O6 • 2HCl |
| Formula Wt. | 517.41 |
| Chemical Name | 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl) amino]- ethyl] amino]-9,10-anthracenedione dihydrochloride |
| IUPAC Name | 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9, 10-dione;dihydrochloride |
| Synonym | Mitoxantrone hydrochloride, Novantrone |
| Melting Point | 160-162°C |
| Solubility | Soluble in water, ethanol, DMSO. |
| Appearance | Blue/Black Crystalline Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Pendleton M, Lindsey RH Jr, Felix CA, et al. Topoisomerase II and leukemia. Ann N Y Acad Sci. 2014 Mar;1310:98-110. PMID: 24495080.
Wan X, Zhang W, Li L, et al. A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling. J Med Chem. 2013 Mar 28;56(6):2619-29. PMID: 23442188.
Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010 Dec 11;376(9757):2009-17. PMID: 21131038.
Mazerski J, Martelli S, Borowski E. The geometry of intercalation complex of antitumor mitoxantrone and ametantrone with DNA: molecular dynamics simulations. Acta Biochim Pol. 1998;45(1):1-11. PMID: 9701490.
